PET/CT 검사에서 Metformin 성분의 항 당뇨약제에 의한 대장에서의 ¹⁸F-FDG 섭취에 관한 연구

¹⁸F-FDG Colonic Uptake by Oral Anti-Diabetic Drugs Including Metfomin in PET/CT Scan

Purpose: The uptake of ¹⁸F-FDG is often observed in normal cell of colon to patients who have noninsulin- dependent diabetes mellitus and had taken anti-diabetic drugs including Metformin in PET/CT scan. In this study, the region of colon was compared between the patients who took anti-diabetic drugs including Metfomin and other patients who took the other anti-diabetic drugs through SUV measurements. Materials and Methods: A hundred eighty patients were studied. 120 patients who have non-insulin-dependent diabetes mellitus (Including Metformin: 60, Excluding Metformin: 60) and 60 patients as a control group were composed. The patient fasted at least 6 hours before receiving an intravenous injection of 370-592 MBq (10-16 mCi) of ¹⁸F-FDG. Scanning from the base of the skull though the mid thigh was performed using the Discovery STe PET/CT Equipment (GE Healthcare, Milwaukee, WI, USA). The highest uptake region was measured SUV among ascending, transverse and descending colon. Results: The values of patients who took the anti-diabetic drugs including Metformin were 6.16±3.64 g/mL, 4.41±2.94 g/mL, and 5.46±2.44 g/mL. The patients who took the anti-diabetic drugs which does not have Metformin were 3.05±1.39 g/mL, 2.08±0.97 g/mL and 3.15±1.85 g/mL. The control group were 2.02±0.88 g/mL, 1.68±0.87 g/mL and 2.19±1.88 g/mL. Conclusion: The effect of the intake of Metformin was observed from the SUV on region of large bowel in this study. Thus, it could be helpful for the results by identifying the ingredient of anti-diabetic drug before the examination and the possibility of interpretation of false positive will be reduced.